Nr 546 Study Guide Rated A+

Acamprosate (Campral) {Ans: · Modulates glutamine transmission, and resembles gamma-aminobutyric acid (GABA) · Good option for clients who must take opioids for chronic pain · Treats withdrawal symptoms · Abstain prior to beginning treatment No affect on Opioids}Why does atomoxetine lack abuse potential {Ans: It increases dopamine levels in the prefrontal cortex but not in the nucleus accumbens}Buprenorphine (Subutex) {Ans: FDA approved for: -Induction of treatmentfor opioid dependence (Bunavail only) -Maintenance treatment of opioid dependence (sublingual) -Maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses (no more than 8 mg) of a transmucosal buprenorphine- containing product (implant) -Moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days (injection)}OCD/Impulsive Control Disorders {Ans: Pharmacologic management is often used in combination with psychotherapy to address eating disorders}Bupenorphrine <18 yo {Ans: Buprenorphine is approved for persons < 18 years of age}Increased negative affect: 5HT, NE Dysfunction {Ans: · depressed mood · guilt · fear/anxiety · hostility · irritability · loneliness · appetite changes}